Evidence map›Paper›PMID 30779461›Full record

Trial reportJournal of clinical laboratory analysis2019

The clinical value of hematological markers in rheumatoid arthritis patients treated with tocilizumab.

Li Zhou, Dong-Mei Xiao, Wen Qin, Bin-Hua Xie, Ting-Hui Wang, Hua Huang, Bao-Jing Zhao, Xi Han, Qing-Qing Sun, Xiu-Di Wu and 1 more

Abstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of clinical laboratory analysis, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Li ZhouDepartment of Rheumatology, Ningbo First Hospital, Ningbo Hospital of Zhejiang University, Ningbo, China.
Dong-Mei XiaoDepartment of Rheumatology, Ningbo First Hospital, Ningbo Hospital of Zhejiang University, Ningbo, China.
Wen QinDepartment of Rheumatology, Ningbo First Hospital, Ningbo Hospital of Zhejiang University, Ningbo, China.
Bin-Hua XieDepartment of Rheumatology, Ningbo First Hospital, Ningbo Hospital of Zhejiang University, Ningbo, China.
Ting-Hui WangDepartment of Rheumatology, Ningbo First Hospital, Ningbo Hospital of Zhejiang University, Ningbo, China.
Hua HuangDepartment of Rheumatology, Ningbo First Hospital, Ningbo Hospital of Zhejiang University, Ningbo, China.
Bao-Jing ZhaoDepartment of Rheumatology, Ningbo First Hospital, Ningbo Hospital of Zhejiang University, Ningbo, China.
Xi HanDepartment of Rheumatology, Ningbo First Hospital, Ningbo Hospital of Zhejiang University, Ningbo, China.
Qing-Qing SunDepartment of Preventive Medicine, Medical School of Ningbo University, Ningbo, China.
Xiu-Di WuDepartment of Rheumatology, Ningbo First Hospital, Ningbo Hospital of Zhejiang University, Ningbo, China.
Han CenDepartment of Preventive Medicine, Medical School of Ningbo University, Ningbo, China.ORCID https://orcid.org/0000-0003-4616-2817

Funding

K.C. Wong Magna Fund in Ningbo UniversityMedical and Health Planned Science and Technology Project of Zhejiang Province 2017KY582National Natural Science Foundation of China 81602921Nature Science Foundation of Ningbo city 2016A610159Ningbo Scientific Innovation Team for Environmental Hazardous Factor Control and Prevention 2016C51001Scientific Research Foundation of Graduate School of Ningbo University
6 · The paper itself

Abstract

backgroundEmerging evidence indicates that some hematological markers have critical value in evaluating treatment response. This study was performed to determine the clinical value of hemoglobin (Hb), platelet (Plt), neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR) in rheumatoid arthritis (RA) patients treated with tocilizumab (TCZ).

methodsFifty-two RA patients receiving TCZ were recruited and followed for 6 months. The values of abovementioned hematological markers were collected. Clinical disease activity index (CDAI) and disease activity score based on 28 joints (DAS28)-ESR were calculated. Correlation analysis was conducted by calculating Pearson's correlation coefficient. The change in disease activity between groups according to the baseline level of hematological markers was compared by t test.

resultsSignificant correlation between change in NLR (△NLR), change in PLR (△PLR), and change in CDAI (△CDAI) was found (△NLR: r = 0.30, P = 0.03; △PLR: r = 0.31, P = 0.03). The change in Plt (△Plt) was correlated with change in DAS28-ESR (△DAS28-ESR) (r = 0.36, P = 8.24 × 10

conclusionOur study demonstrated that △Plt, △NLR, and △PLR could be used to monitor the clinical response to TCZ. RA patients with high baseline levels of Plt, NLR, and PLR achieved more improvement, indicating these hematological markers might be utilized to guide TCZ treatment.

Indexed as

AdultAntibodies, Monoclonal, HumanizedArthritis, RheumatoidBiomarkersFemaleHemoglobinsHumansLymphocyte CountMaleMiddle AgedNeutrophilsPlatelet CountProspective StudiesTreatment OutcomeAntibodies, Monoclonal, HumanizedBiomarkersHemoglobinstocilizumabhemoglobinneutrophil-to-lymphocyte ratioplatelet-to-lymphocyte ratiorheumatoid arthritistocilizumab

Identifiers

PMID30779461
PMCPMC6595377

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.